The Year Ahead: Bisphosphonate Class Faces Generic Competition – Fosamax Goes Off Patent

Merck's Fosamax (alendronate) will be one of the key branded drugs facing generic competition in 2008, and the availability of a low-cost version of the market-leading osteoporosis drug could have a wide-reaching impact on the bisphosphonate class and beyond